¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"long patch pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sensory pathway
    °¨°¢·Î
  • ubiquitin-protease pathway
    À¯ºñÄûƾ´Ü¹éºÐÇØÈ¿¼ÒÅë·Î
  • visual pathway
    ½Ã°¢°æ·Î
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • direct oxidative pathway
    Á÷Á¢»êÈ­°æ·Î.
  • dopaminergic pathway
    µµÆÄ¹Î °æ·Î
  • extrinsic pathway
    ¿ÜÀμº °æ·Î.
  • extrinsic pathway
    ¿ÜÀμº °æ·Î(ÌèÖØ)
  • final common pathway
    ÃÖÁ¾°øÅë°æ·Î.
  • glucuronic acid pathway
    ±Û·çÄí·Ð»ê°æ·Î.
  • glycolytic pathway
    ÇØ´ç°æ·Î
  • intrinsic pathway
    ³»Àμº °æ·Î(Ò®ì×àõÌèÖØ).
  • lipoxygenase pathway
    Áö¹æ»êÈ­È¿¼Ò°æ·Î(¡­ß«ûùý£áÈÌèÖØ)
  • mesolimbic-mesocortical pathway
    Áߺ¯¿¬°è-ÁßÇÇÁú°æ·Î(ñéÜ«æÞÍ£-ñéù«òõÌèÖØ)
  • metabolic pathway
    ´ë»ç°æ·Î.
  • neurohumoral pathway
    ½Å°æ¾×¼º °æ·Î(~ÌèÖØ).
  • nigrostriatal pathway
  • oculomotor pathway
    ¾È±¸¿îµ¿½Å°æ·Î(äÑÏ¹ê¡ ÔÑãêÌèÖØ).
  • optic pathway
    ½Ã·Î.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • intrinsic pathway
    ³»ÀÎ °æ·Î(Ò®ì×ÌèÖØ)
  • -ketoadipate pathway
    -ÄÉÅ侯µðÇÁ»ê(ß«)°æ·Î(ÌèÖØ)
  • -ketoglutrate pathway
    -ÄÉÅ䱸¸£Å¸¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • layered metabolic pathway
    Ãþ´ë»ç°æ·Î(öµÓÛÞóÌèÖØ)
  • linear metabolic pathway
    ¼±Çü ´ë»ç°æ·Î(àÊû¡ÓÛÞóÌèÖØ)
  • mandelate pathway
    ¸¸µ¨»ê(ß«) °æ·Î(ÌèÖØ)
  • metabolic pathway
    ´ë»ç °æ·Î(ÓÛÞóÌèÖØ)
  • oxaloacetate pathway
    ¿Á»ì¾Æ¼¼Æ®»ê(ß«) °æ·Î(ÌèÖØ)
  • pathway
    °æ·Î(ÌèÖØ)
  • pentose phosphate pathway
    Àλê(×òß«ÆæÅ佺 °æ·Î(ÌèÖØ)
  • pentose phosphoketolase pathway
    ÆæÅ佺 Æ÷½ºÆ÷ÄÉÅç·¹À̽º °æ·Î(ÌèÖØ)
  • phosphogluconate oxidative pathway
    Æ÷½ºÆ÷±Û·çÄÜ»ê(ß«) »êÈ­°æ·Î(ß«ûùÌèÖØ)
  • phosphogluconate pathway
    Æ÷½ºÆ÷±Û·çÄÜ»ê °æ·Î(ÌèÖØ)
  • phosphoketolase pathway
    Æ÷½ºÆ÷ÄÉÅç·¹À̽º °æ·Î(ÌèÖØ)
  • properdin pathway
    ÇÁ·ÎÆä¸£µò °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PAP pancreatitis-associated protein; Papanicolaou [test]; papaverine; passive-aggressive personality; pa...
PBP penicillin-binding protein; porphyrin biosynthesis pathway; prostate-binding protein; pseudobulbar p...
PPP pain perception profile; palatopharyngoplasty; palmoplantar pustulosis; pentose phosphate pathway; p...
RMP rapidly miscible pool; regional medical program; regional myocardial infarction; resting membrane po...
RuMP ribulose monophosphate pathway
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TFPI-2 Tissue factor pathway inhibitor-2
APC alternative pathway of complement
FP fast pathway
GSP general secretory pathway
PP perforant pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dorsal column pathway
    ¹è ôÁÖ °æ·Î
    Ã˰¢ÀÇ A
  • efferent neural pathway
    ¿ø½É¼º ½Å°æ·Î
    ÁßÃ߽Űæ°è·ÎºÎÅÍ Àü´ÞµÇ¾î ³ª°¡´Â ½Å°æ ÀÓÆÞ½º.
  • humoral pathway
    ü¾× Åë·Î
  • intrinsic pathway
    ³»ºÎ °æ·Î, ³»Àμº °æ·Î
  • medial pathway
    ³»Ãø °æ·Î
  • meridian pathway
    °æ¶ô, °æ·Î
    µ¿¾ç ÀÇÇп¡¼­ ¹°¸® ¿ä¹ý, ƯÈ÷ ħ±¸ Ä¡·áÀÇ À̷Рü°è·Î¼­ Áß¿ä½ÃµÇ´Â °æÇ÷
  • metabolic pathway
    ´ë»ç °æ·Î
  • neural pathway
    ½Å°æ °æ·Î, ½Å°æ Åë·Î
    ÀÓÆÞ½º°¡ Àü´ÞµÇ´Â ½Å°æ ±¸Á¶¹°.
  • orbiting pathway
    ±Ëµµ
  • paleothalamic pathway
    °í½Ã»ó Àü´Þ·Î
  • paramedian pathway
    Á¤Áß¹æ °æ·Î
  • pathway
    °æ·Î, Àüµµ·Î
    Àüµµ·Î¶ó°í ÇÏ´Â °ÍÀº ³ú ¶Ç´Â ô¼ö¿¡ À־ÀÇ ÁßÃß¿Í ½Åü ¸»Ãʸ¦ ¿¬°áÇÏ´Â Åõ»ç ½Å°æ·Î¸¦ ¸»ÇÏ´Â °ÍÀ¸·Î Åõ»ç ½Å°æ·Î´Â ½Ä¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °Í°ú µ¿¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °ÍÀ¸·Î ´ëº°ÇÒ ¼ö ÀÖ´Ù. ±×ÀÇ ¾î´À °Í¿¡µµ »óÇ༺
  • pentose hosphate pathway

    pentose nucleic acid (ÆæÅ佺 ÇÙ»ê

  • salvage pathway
    ±¸Á¦ °æ·Î, ÀçÀÌ¿ë °æ·Î
    ±âÁ¸ ¹°ÁúÀ» »ç¿ëÇØ ÇÕ¼ºÇÏ´Â °æ·Î.
  • secondary pathway
    ÀÌÂ÷ °æ·Î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
de novo pathway <biochemistry> A pathway for synthesising a biomolecule from simple precursor molecules.
Compare: salvage pathway.
(12 Jan 1998)
DNA repair pathway The sequence of steps in the repair of DNA. Each step is governed by an enzyme.
(12 Dec 1998)
drug development pathway The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing.
(14 Nov 1997)
intrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
Embden-Meyerhof-Parnas pathway A pathway that degrades glucose to pyruvate, the six-carbon stage converts glucose to fructose-1,6-bisphosphate, and the three-carbon stage produces ATP while changing glyceraldehyde-3-phosphate to pyruvate.
Compare: Entner-Doudoroff pathway.
(09 Oct 1997)
Embden-Meyerhof pathway The main pathway for anerobic degradation of carbohydrate. Starch or glycogen is hydrolysed to glucose 1 phosphate and then through a series of intermediates, yielding two ATP molecules per glucose and producing either pyruvate which feeds into the tricarboxylic acid cycle) or lactate.
(18 Nov 1997)
Entner-Douderoff pathway A degradative pathway for carbohydrates in certain microorganisms (e.g., Pseudomonas sp.) that lack hexokinase, phosphofructokinase, and glyceraldehyde-3-phosphate dehydrogenase.
(05 Mar 2000)
Entner-Doudoroff pathway <biochemistry> A pathway that converts glucose to pyruvate and glyceraldehyde-3 phosphate by producing 6-phosphogluconate and then dehydrating it.
(09 Oct 1997)
extrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
4-aminobutyrate pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
lysogenic pathway <virology> The method by which a virus becomes a dormant, passive part of its host bacterium's genome (a lysogenic virus), choosing to insert its DNA into the host's and postponing completion of its lytic cycle, at which time it destroys the host and spreads its progeny to infect other bacterial cells (enters the lytic pathway).
(09 Oct 1997)
lytic pathway The steps in the method that a virus takes to complete a lytic cycle, including the production and assembly of progeny viruses with host cell machinery and the destruction of the host cell by rupturing its plasma membrane (lysis), releasing the progeny viruses in the process.
(09 Oct 1997)
HIV long-terminal repeat Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription.
(12 Dec 1998)
segment long spacing <biochemistry> Abnormal packing pattern of collagen molecules formed if ATP is added to acidic collagen solutions, in which lateral aggregates of molecules are produced.
Each aggregate is 300 nm long and the molecules are all in register. If segment long spacing aggregates are overlapped with a quarter stagger, the 67 nm banding pattern of normal fibrils is reconstituted.
Acronym: SLS
(18 Nov 1997)
insurance, long-term care Health insurance to provide full or partial coverage for long-term home care services or for long-term nursing care provided in a residential facility such as a nursing home.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • long hours
    ¹ã11½Ã¶Ç´Â12½Ã
  • long hundredweight
    112ÆÄ¿îµå
  • long interest
    (°­¼¼°¡ ¿¹»óµÇ´Â)ÁÖ½ÃÀÇ º¸À¯¼ö
  • long johns
    (¼Õ¸ñ,¹ß¸ñ±îÁö ÀÖ´Â) ±ä¼Ó¿Ê
  • long jump
    ³ÐÀ̶ٱâ
  • long man
    ·Õ ¸Ç(ÇÑ ÆÐ½ºÇ÷¹ÀÌ·¹¼­ °¡Àå ±í¼÷ÇÑ ÁöÁ¡±îÁö ´Þ¸®´Â ¸®½Ã¹ö)
  • long measure
    ôµµ
  • long meter
    ÀåÀ²(º¸Åë ¾à°­ °Ý 8À½Àý4ÇàÀ¸·Î µÈ Âù¼Û°¡Á¶)
  • long off
    (Å©¸®ÄÏ)Åõ¼öÀ§ ÁÂÈĹæÀÇ ¾ß¼ö
  • long on
    (Å©¸®ÄÏ)Åõ¼öÀÇ ¿ìÈĹæÀÇ ¾ß¼ö
  • long pig
    ÀÎÀ°;ÀÎü
  • long play
    LPÆÇ ·¹ÄÚµå
  • long position
    »ó½Â ±â´ëÁÖ¸¦ ¸ÅÀÔ;º¸À¯ÇÑ »óÅÂ(»ç¶÷)
  • long pull
    Àå±â¿¡ °ÉÄ£ ÀÏ;Àå°Å¸® ¿©Çà;ÇÑÀÜ ´õ ÁÖ±â(¼Õ´ÔÀ» ²ø±â À§ÇØ)
  • long purchase
    °­¼¼ ¿¹»óÁÖ ¸ÅÀÔ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á